Skip to main content

Table 1 Characteristics of participants

From: Delivering synaptic protein mRNAs via extracellular vesicles ameliorates cognitive impairment in a mouse model of Alzheimer’s disease

Characteristic

Total sample (n = 113)

Controls (n = 56)

AD (n = 57)

Age, mean (SD)

74.6 (6.9)

76.1 (6.4)

73.1 (7.0)

Education year, mean (SD)

9.6 (2.3)

9.9 (2.2)

9.2 (2.4)

Women, No. (%)

57 (50.4)

28 (50.0)

29 (50.9)

APOE ε4 positive, No. (%)

36 (31.9)

10 (17.9)

26 (45.6)a

MMSE score, mean (SD)

23.0 (6.4)

29.0 (0.6)

17.0 (3.1)a

ADAS-Cog, mean (SD)

13.1(9.4)

5.4 (2.4)

20.7 (7.3)a

Aβ42 (pg/ml), mean (SD)

539.7 (216.0)

720.4 (146.4)

362.1 (86.4)a

P-tau (pg/ml), mean (SD)

91.3 (58.4)

53.1 (23.6)

128.9 (58.1)a

T-tau (pg/ml), mean (SD)

485.1 (208.1)

326.7 (79.8)

640.8 (175.0)a

MTA score distribution, No. (%)

   

 MTA = 0

40 (35.4)

40 (71.4)

0 (0)

 MTA = 1

16 (14.2)

16 (28.6)

0 (0)

 MTA = 2

39 (34.5)

0 (0)

39 (68.4)

 MTA = 3

13 (11.5)

0 (0)

13 (22.8)

 MTA = 4

5 (4.4)

0 (0)

5 (8.8)

  1. The values of age, education year, MMSE, ADAS-Cog, and cerebrospinal fluid biomarkers are shown as mean (standard deviation). 
  2. Abbreviations: Aβ amyloid-β, AD Alzheimer’s disease, ADAS-Cog the Alzheimer’s Disease assessment scale cognitive subscale, APOE apolipoprotein E, MMSE Mini-Mental State Examination, MTA Medial temporal lobe atrophy, P-tau Phosphorylated tau, SD Standard deviation, T-tau Total tau
  3. aP < 0.05 compared to controls